<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Contineum Therapeutics, Inc. Class A Common Stock — News on 6ix</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock</link>
<description>Latest news and press releases for Contineum Therapeutics, Inc. Class A Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 05 Mar 2026 21:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/contineum-therapeutics-inc-class-a-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355a8978dffbe2df0eb84f.webp</url>
<title>Contineum Therapeutics, Inc. Class A Common Stock</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock</link>
</image>
<item>
<title>Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-fourth-quarter-2025-financial-results-affirms-key-clinical-development-milestones-68</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-fourth-quarter-2025-financial-results-affirms-key-clinical-development-milestones-68</guid>
<pubDate>Thu, 05 Mar 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, March 05, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones.</description>
</item>
<item>
<title>Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-to-present-at-the-2026-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-to-present-at-the-2026-leerink-partners-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, March 03, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET.</description>
</item>
<item>
<title>Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-inducement-grant-210500331</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-inducement-grant-210500331</guid>
<pubDate>Wed, 28 Jan 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, January 28, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on January 26, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 23,000 shares of Class A common stoc</description>
</item>
<item>
<title>Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-announces-pricing-upsized-032400921</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-announces-pricing-upsized-032400921</guid>
<pubDate>Fri, 12 Dec 2025 03:24:00 GMT</pubDate>
<description>SAN DIEGO, December 12, 2025--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share. In addition, Contineum has granted the underwriters a 30-day option t</description>
</item>
<item>
<title>Contineum Therapeutics Announces Proposed $75.0 Million Public Offering</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-announces-proposed-75-210500827</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-announces-proposed-75-210500827</guid>
<pubDate>Thu, 11 Dec 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, December 11, 2025--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the commencement of an underwritten public offering of $75.0 million of shares of its Class A common stock. In addition, Contineum intends to grant the underwriters a 30-day option to purchase up to an additional $11.25</description>
</item>
<item>
<title>Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-attend-8th-annual-210500342</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-attend-8th-annual-210500342</guid>
<pubDate>Mon, 24 Nov 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, November 24, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on Wednesday, December 3, 2025 at 1:20 p.m. ET.</description>
</item>
<item>
<title>Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-topline-data-210500938</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-topline-data-210500938</guid>
<pubDate>Thu, 20 Nov 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, November 20, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).</description>
</item>
<item>
<title>Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-third-quarter-200500024</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-third-quarter-200500024</guid>
<pubDate>Thu, 30 Oct 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, October 30, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its third-quarter 2025 financial results and affirmed its key clinical development milestones.</description>
</item>
<item>
<title>Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-positive-topline-120500509</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-positive-topline-120500509</guid>
<pubDate>Thu, 18 Sep 2025 12:05:00 GMT</pubDate>
<description>SAN DIEGO, September 18, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced positive topline data from its PIPE-791 Phase 1b positron emission tomography (PET) trial. The trial met its primary objectives by demonstrating PIPE-791, the Company’s novel, brain penetrant, small molecule antagonist</description>
</item>
<item>
<title>Contineum Therapeutics to Present at September Investor Conferences</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-present-september-investor-200500500</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-present-september-investor-200500500</guid>
<pubDate>Thu, 28 Aug 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, August 28, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September.</description>
</item>
<item>
<title>Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-second-quarter-200500318</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-second-quarter-200500318</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, August 05, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its second-quarter 2025 financial results and updated its key clinical development milestones.</description>
</item>
<item>
<title>Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-provides-phase-1b-121500977</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-provides-phase-1b-121500977</guid>
<pubDate>Wed, 25 Jun 2025 12:15:00 GMT</pubDate>
<description>SAN DIEGO, June 25, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progres</description>
</item>
<item>
<title>Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-present-2025-rbc-200500519</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-present-2025-rbc-200500519</guid>
<pubDate>Thu, 15 May 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, May 15, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Conti</description>
</item>
<item>
<title>Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-first-quarter-200500966</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-first-quarter-200500966</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, May 14, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2025 financial results and affirmed its key clinical development milestones.</description>
</item>
<item>
<title>Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-appoints-timothy-watkins-200500814</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-appoints-timothy-watkins-200500814</guid>
<pubDate>Mon, 28 Apr 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, April 28, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company’s executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affair</description>
</item>
<item>
<title>Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-announces-appointment-diego-200500029</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-announces-appointment-diego-200500029</guid>
<pubDate>Mon, 17 Mar 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, March 17, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025.</description>
</item>
<item>
<title>Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-present-stifel-2025-200500444</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-present-stifel-2025-200500444</guid>
<pubDate>Wed, 12 Mar 2025 20:05:00 GMT</pubDate>
<description>SAN DIEGO, March 12, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A w</description>
</item>
<item>
<title>Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-fourth-quarter-210500130</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-reports-fourth-quarter-210500130</guid>
<pubDate>Thu, 06 Mar 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, March 06, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2024 financial results and affirmed its key clinical development milestones.</description>
</item>
<item>
<title>Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-initiates-patient-dosing-210500684</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-initiates-patient-dosing-210500684</guid>
<pubDate>Tue, 04 Mar 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, March 04, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid</description>
</item>
<item>
<title>Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-present-2025-leerink-210500502</link>
<guid isPermaLink="true">https://6ix.com/company/contineum-therapeutics-inc-class-a-common-stock/news/contineum-therapeutics-present-2025-leerink-210500502</guid>
<pubDate>Mon, 03 Mar 2025 21:05:00 GMT</pubDate>
<description>SAN DIEGO, March 03, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Cont</description>
</item>
</channel>
</rss>